Axicabtagene ciloleucel is a chimeric antigen receptor T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. This includes diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and subtypes of DLBCL (e.g., primary mediastinal large B-cell lymphoma and DLBCL arising from follicular lymphoma).
CADTH completed a review of manufacturer-submitted materials and published literature to assess the clinical impact, cost-effectiveness, implementation considerations (including patient and caregiver perspectives and experiences, and other factors such as facilities, eligibility, travel, and resource costs), and ethical considerations associated with the provision of axicabtagene ciloleucel therapy in Canada.
The project includes the following key components:
- clinical systematic review
- economic review
- review of implementation considerations, ethics, and patient and caregiver perspectives and experiences
- recommendations report.